The study aims to determine whether next generation sequencing and microsatellite analysis of cervical cytology is sensitive for the detection of endometrial carcinoma.
Definitive diagnosis of endometrial cancer relies on endometrial biopsy, in addition to imaging. Biopsy is however invasive and often painful, and its sensitivity in only moderate. Cervical cytology could be an alternative. This is a proof-of-concept study. The investigators will carry out next generation sequencing of cervical cytology in patients with confirmed endometrial carcinoma, in order to determine whether activating variants are identified. About 15% of endometrial carcinomas are microsatellite instable (MSI). The investigators will therefore also carry out MSI analysis using MSICare in the subset of cases with MMR-deficient cancer.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
100
Cervical cytology will be performed by the surgeon in the operating theatre before hysterectomy.
Medical genetics department
Paris, France
RECRUITINGActivating variants and MSI via cytology
proportion of cases in whom genetic activating variants and microsatellite instability are detected by cytology
Time frame: 16 months
Type of variants
Variant details
Time frame: 16 months
Number of variants
Variant details
Time frame: 16 months
Frequency of variants
Variant details
Time frame: 16 months
Comparison with the proportion of variants seen on the pathological
Tumoral correlation
Time frame: 16 months
Comparison with the proportion of microsatellite instability detected on the pathological specimen.
Tumoral correlation
Time frame: 16 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.